We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
+28.33%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$131M
AUM Growth
+$39.1M
(+43%)
Cap. Flow
+$20.1M
Cap. Flow
% of AUM
15.4%
Top 10 Holdings %
Top 10 Hldgs %
60.52%
Holding
43
New
14
Increased
9
Reduced
9
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SAGE
Sage Therapeutics
SAGE
|
+$7.16M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$5.81M |
| 3 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$4.7M |
| 4 |
NSTG
NanoString Technologies, Inc.
NSTG
|
+$4.32M |
| 5 |
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
|
+$4.23M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$6.15M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$4.62M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$4.24M |
| 4 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$3.41M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$2.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.37% |
| 2 | Financials | 1.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BMY.RT
1
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $12.7M | 9.76% |
3,558,046
+1,173,559
| +49% | +$4.23M |
|
|
ARNA
2
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $10.9M | 8.34% |
172,896
-76,970
| -31% | -$4.24M |
|
|
GBT
3
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $10.8M | 8.29% |
171,316
+84,739
| +98% | +$5.81M |
|
|
SAGE
4
DELISTED
Sage Therapeutics
SAGE
| $8.2M | 6.28% |
+197,249
| New | +$7.16M |
|
5
Guardant Health
GH
$19.2B
| $7.79M | 5.97% |
96,039
+19,601
| +26% | +$1.58M |
|
6
Ascendis Pharma A/S
ASND
$16.6B
| $7.04M | 5.39% |
47,599
+19,442
| +69% | +$2.67M |
|
|
NSTG
7
DELISTED
NanoString Technologies, Inc.
NSTG
| $6.45M | 4.94% |
219,577
+145,076
| +195% | +$4.32M |
|
|
MNTA
8
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $5.3M | 4.06% |
159,197
+76,110
| +92% | +$2.42M |
|
9
Centene
CNC
$30.4B
| $4.92M | 3.77% |
77,402
+61,084
| +374% | +$3.98M |
|
10
Cytokinetics
CYTK
$10.7B
| $4.86M | 3.72% |
206,086
+1,835
| +0.9% | +$34.4K |
|
11
10x Genomics
TXG
$5.85B
| $4.54M | 3.48% |
50,819
+26,216
| +107% | +$2.04M |
|
|
AVDL
12
DELISTED
Avadel Pharmaceuticals
AVDL
| $4.31M | 3.3% |
+533,632
| New | +$4.7M |
|
13
UnitedHealth
UNH
$382B
| $3.81M | 2.92% |
12,904
-2,907
| -18% | -$833K |
|
14
Fate Therapeutics
FATE
$276M
| $3.75M | 2.87% |
109,165
-10,938
| -9% | -$326K |
|
15
PTC Therapeutics
PTCT
$6.19B
| $3.74M | 2.87% |
73,708
-26,762
| -27% | -$1.31M |
|
|
ATRS
16
DELISTED
Antares Pharma, Inc.
ATRS
| $3.57M | 2.74% |
+1,299,202
| New | +$3.63M |
|
|
FOLD
17
DELISTED
Amicus Therapeutics
FOLD
| $3.54M | 2.71% |
234,753
-83,399
| -26% | -$1.02M |
|
|
18
Bio-Rad Laboratories Class A
BIO
$8.78B
| $2.9M | 2.23% |
6,434
-6,242
| -49% | -$2.75M |
|
19
BioNTech
BNTX
$23.7B
| $2.58M | 1.98% |
+38,626
| New | +$1.93M |
|
20
Twist Bioscience
TWST
$5.33B
| $2.42M | 1.85% |
53,344
-70,776
| -57% | -$2.54M |
|
|
CYPH
21
Cypherpunk Technologies Inc
CYPH
$63M
| $1.88M | 1.44% |
+90,073
| New | +$1.93M |
|
|
AIMT
22
DELISTED
Aimmune Therapeutics
AIMT
| $1.68M | 1.29% |
+100,544
| New | +$1.71M |
|
23
Dianthus Therapeutics
DNTH
$5.71B
| $1.58M | 1.21% |
+13,191
| New | +$1.86M |
|
|
BLUE
24
DELISTED
bluebird bio
BLUE
| $1.53M | 1.17% |
+1,930
| New | +$1.46M |
|
|
MRNS
25
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $1.49M | 1.14% |
146,561
-67,269
| -31% | -$619K |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Asymmetry Capital Management held 43 positions worth $131M, up 43% from $91.4M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Asymmetry Capital Management deployed $20.1M of net new capital in Q2 2020, opening 14 new positions and adding to 9 existing holdings. Its largest new stake was Sage Therapeutics: 197,249 shares worth $8.2M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Arena Pharmaceuticals Inc, an estimated $4.24M trimmed.
- Asymmetry Capital Management's largest Q2 2020 buy was Sage Therapeutics: 197,249 shares worth $8.2M.
- Asymmetry Capital Management added most to Global Blood Therapeutics, Inc. in Q2 2020, an estimated $5.81M increase.
- Asymmetry Capital Management's biggest Q2 2020 reduction was Arena Pharmaceuticals Inc, cutting an estimated $4.24M.
- Asymmetry Capital Management fully exited Baxter International in Q2 2020, selling an estimated $6.15M.
- Asymmetry Capital Management's ten largest holdings make up 61% of its $131M portfolio in Q2 2020.
- Asymmetry Capital Management opened 14 new positions and closed 11 in Q2 2020.
- Asymmetry Capital Management's portfolio value rose 43% quarter-over-quarter to $131M.
Based on Asymmetry Capital Management's 13F filing for Q2 2020, filed 6 Aug 2020.